مسار بولونيا
AR

مروة سعد جودة جبر

السنة عنوان البحث نشر البحث
2021 Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer Systematic Reviews in Pharmacy
The cellular availability of NAD+ is essential for Sirtuin 1 (SIRT1), a class III histone deacetylase, catalytic activity which make it as a reliable metabolic sensor. For evidence, SIRT1 had a high expression in tissue with metabolic activity including muscle, brain, liver, pancreas, and adipose tissue. Previous reports have documented the crosstalk between SIRT1 and nuclear factor kappa-B (NF-κB) signaling in conditions such as lymphoma, leukemia, and myeloma. The purpose of present study is to find the relationships between SIRT1 and NF-κB activation on pancreatic cancer cells (Capan-2, AsPC-1, and BxPC-3). We found the activation of NF-κB was inhibited by use 1 µM SIRT1 aptamer by increased the activity of SIRT1 protein. Overall, our findings suggested that SIRT1 activation resulting in inhibition of pancreatic cancer cells growth and significantly repression of NF-κB proteins activation, this activation of SIRT1 by aptamer may be considered as a potential future therapy for cancer especially pancreatic cancer.